Acute stroke therapies (Q41169631)

27 September 2017

1 reference

title

Acute stroke therapies (English)

1 reference

27 September 2017

Brint SU

1

1 reference

27 September 2017

publication date

1 November 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

46

1 reference

27 September 2017

issue

5

1 reference

27 September 2017

page(s)

446-449

1 reference

Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Development of aspirin resistance in persons with previous ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Controlled Trial of Ancrod in Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Pharmacokinetic optimisation of the treatment of embolic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0090-3019%2896%2900347-3

7 January 2021

10.1016/S0090-3019(96)00347-3

Identifiers

DOI

1 reference

27 September 2017

1 reference